BMC Cancer 2005, 5:45.PubMedCrossRef 42. Li T, Li RS, Li YH, Zhong S, Chen YY, Zhang CM, Hu MM, Shen ZJ: miR-21 as an Independent Biochemical Recurrence Predictor and Potential Therapeutic PD0332991 in vivo Target for Prostate Cancer. J Urol 2012, 187:1466–1472.PubMedCrossRef 43. Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA: MicroRNA molecular profiles associated with diagnosis, clinicopathologic www.selleckchem.com/products/tariquidar.html criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.
Clin Cancer Res 2012, 18:534–545.PubMedCrossRef 44. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425–436.PubMedCrossRef 45. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, Dunant Selleck Liproxstatin-1 A, Pham TC, Petrini I, Lee A, Khan MA, Hainaut P, Pignon JP, Brambilla E, Popper HH, Filipits M, Harris CC, Giaccone G: MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010, 70:8288–8298.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions PG conceived
the study and drafted the manuscript. PG and ZY collected and analyzed the data, PG and ZY also secured funding. XL, WW and BZ contributed to the quality control of study inclusion and discussion. All authors read and approved the final manuscript.”
“Background Clear cell adenocarcinoma (CCC) is a distinct entity from other epithelial ovarian carcinomas (EOC). CCC is thought to arise from endometriosis or clear cell adenofibroma, however, the origin of serous cyst adenocarcinoma (SCA) is thought to be Mullerian epithelium derived from either ovarian surface epithelium or fallopian tube (endosalpingiosis). CCC has specific biological and clinical behavior, compared with other histological types. However, in the studies used as evidence for recommended
treatment as standard treatment of EOC, most of the enrolled patients were not clear cell histology, and these study results do not provide a scientific rationale for CCC. In Molecular motor this review, we summarize the treatment of CCC. Surgical treatment The standard surgical treatment of patients with EOC is based on hysterectomy, bilateral salpingo-oophorectomy and partial omentectomy with peritoneal sampling and lymphadenectomy, and cytoreductive surgery is added especially for advanced cases. The surgical treatment of CCC is usually determined based on the guideline of EOC. In this section, we summarize the surgical treatment of CCC patients. Surgical staging It has been reported that the incidence of lymph node metastasis in stage I (pT1) EOC was approximately 5-20% [1–6].